Occudo Quantitative Strategies’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,654
Closed -$2.13M 821
2026
Q1
$2.13M Buy
+5,654
New +$1.86M 0.12% 248
2025
Q4
Sell
-1,426
Closed -$461K 748
2025
Q3
$461K Buy
1,426
+492
+53% +$153K 0.06% 411
2025
Q2
$363K Buy
+934
New +$376K 0.04% 420
2025
Q1
Sell
-9,574
Closed -$3.53M 719
2024
Q4
$3.53M Buy
+9,574
New +$4.01M 0.64% 25
2023
Q4
Sell
-5,389
Closed -$2.35M 899
2023
Q3
$2.35M Sell
5,389
-323
-6% -$147K 0.3% 70
2023
Q2
$2.54M Buy
+5,712
New +$2.64M 0.26% 89
2023
Q1
Sell
-3,586
Closed -$1.84M 978
2022
Q4
$1.84M Buy
3,586
+2,799
+356% +$1.42M 0.21% 135
2022
Q3
$357K Sell
787
-5,163
-87% -$2.47M 0.03% 789
2022
Q2
$2.87M Buy
+5,950
New +$2.94M 0.24% 108
2022
Q1
Sell
-1,755
Closed -$814K 1174
2021
Q4
$814K Buy
1,755
+883
+101% +$371K 0.07% 434
2021
Q3
$325K Buy
+872
New +$331K 0.04% 700
2021
Q1
Sell
-1,041
Closed -$334K 800
2020
Q4
$334K Buy
+1,041
New +$319K 0.1% 374

Other funds holding ELV

Occudo Quantitative Strategies's ELV Position: Q2 2026 in Review

Occudo Quantitative Strategies sold out of Elevance Health (ELV) in Q2 2026, closing a stake of 5,654 shares — an estimated $2.13M sold.

Occudo Quantitative Strategies first reported a position in ELV in Q4 2020 and held it in 12 quarters. The position peaked at $3.53M in Q4 2024. 1,607 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Occudo Quantitative Strategies reported no remaining Elevance Health position as of Q2 2026 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 5,654 Elevance Health shares in Q2 2026, an estimated $2.13M.
  • Occudo Quantitative Strategies first reported a position in Elevance Health in Q4 2020 and held it in 12 quarters.
  • Occudo Quantitative Strategies's Elevance Health position peaked at $3.53M in Q4 2024.
  • 1,607 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.